U.S., March 13 -- ClinicalTrials.gov registry received information related to the study (NCT07466394) titled 'COGSCREEN II: Early Detection of Cognitive Impairment' on Feb. 25.
Brief Summary: While knowledge about dementia and its causes is increasing rapidly, healthcare systems remain ill-equipped to detect cognitive decline in the early stages of neurodegenerative diseases such as Alzheimer's disease (AD). However, improving the early identification of AD in the population is a prerequisite for dementia prevention and providing future disease-modifying treatments for individuals most likely to benefit. Subjective cognitive deficits (SCD) and mild cognitive impairment (MCI) may indicate prodromal AD, even in the absence of functional impa...